Drilldown: Medicines

None (3)

Other values:

Search

None (70) · Aduhelm (1) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Edronax (1) · Fetzima (1) · Kisunla (1) · Leqembi (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Irreversible non-selective MAO inhibitor (3) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · None (2) · Contains LSA (2) · Contains mescaline (2) · Serotonin–norepinephrine reuptake inhibitor (2)

Other values:

Search

None (88) · Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) · Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) · Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1)

None (88) · 10 mg/kg IV every 2 weeks (1) · 25 mg (1) · 700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance (1) · Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w (1)

None (88) · 200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 350 mg/20 mL vial for IV infusion (1) · Was: 170 mg/1.7 mL, 300 mg/3 mL vials for IV infusion (1)

None (88) · 10 mg/kg q2w (1) · 1400 mg q4w (1) · 200 mg/d (1) · Withdrawn 2024 (1)

None (86) · IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1) · IV infusion every 4 weeks (2) · Oral (3)

None (86) · 30–60 minutes (1) · Amyloid PET clearance within months; cognitive benefit over 18 months (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · PET Aβ reduction over months (1) · Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1)

None (86) · 8–12 hours (1) · Chronic daily dosing (1) · Long (1) · Ongoing dosing (1) · Treatment can be discontinued upon achieving amyloid clearance (1) · Withdrawn (1)

None (86) · 3–5 hours (1) · ~12 hours (1) · ~12.1 days (1) · ~25 days (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~5-7 days (1)

None (86) · 100% (IV) (3) · 70–90% (oral) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~50% (highly variable) (1)

None (86) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Discontinued/withdrawn (1) · Limited data (2) · Not established (1)

None (86) · Rx-only (1) · Rx-only in US (1) · Rx; ARIA monitoring required (1) · Rx; REMS-like program for ARIA monitoring (1) · Schedule I (United States) (1) · Withdrawn from US market January 2024 (1)